Overview

Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled clinical multicenter study.At the same time, the effects of exercise tolerance and quality of life were also observed.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Hutchison Pharmaceuticals Limited